<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE ichicsr SYSTEM "http://www.accessdata.fda.gov/xml/icsr-xml-v2.1.dtd">
<ichicsr lang="en">
	<ichicsrmessageheader>
		<messagetype>ichicsr</messagetype>
		<messageformatversion>2.1</messageformatversion>
		<messageformatrelease>2.0</messageformatrelease>
		<messagenumb>734880_111</messagenumb>
		<messagesenderidentifier>LILLYFDA</messagesenderidentifier>
		<messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
		<messagedateformat>204</messagedateformat>
		<messagedate>20130125151006</messagedate>
	</ichicsrmessageheader>
	<safetyreport>
		<safetyreportversion>2</safetyreportversion>
		<safetyreportid>KR-ELI_LILLY_AND_COMPANY-KR201212005061</safetyreportid>
		<primarysourcecountry>KR</primarysourcecountry>
		<occurcountry>KR</occurcountry>
		<transmissiondateformat>102</transmissiondateformat>
		<transmissiondate>20130116</transmissiondate>
		<reporttype>1</reporttype>
		<serious>1</serious>
		<seriousnessdeath>2</seriousnessdeath>
		<seriousnesslifethreatening>2</seriousnesslifethreatening>
		<seriousnesshospitalization>1</seriousnesshospitalization>
		<seriousnessdisabling>2</seriousnessdisabling>
		<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
		<seriousnessother>2</seriousnessother>
		<receivedateformat>102</receivedateformat>
		<receivedate>20121217</receivedate>
		<receiptdateformat>102</receiptdateformat>
		<receiptdate>20130114</receiptdate>
		<additionaldocument>2</additionaldocument>
		<fulfillexpeditecriteria>1</fulfillexpeditecriteria>
		<companynumb>KR-ELI_LILLY_AND_COMPANY-KR201212005061</companynumb>
		<medicallyconfirm>2</medicallyconfirm>
		<primarysource>
			<reportercountry>KR</reportercountry>
			<qualification>5</qualification>
		</primarysource>
		<primarysource>
			<reportercountry>KR</reportercountry>
			<qualification>5</qualification>
		</primarysource>
		<sender>
			<sendertype>1</sendertype>
			<senderorganization>Eli Lilly and Company</senderorganization>
			<senderdepartment>BS200</senderdepartment>
			<sendertitle>Mr.</sendertitle>
			<sendergivename>John</sendergivename>
			<sendermiddlename>A.</sendermiddlename>
			<senderfamilyname>Fredenburg</senderfamilyname>
			<senderstreetaddress>Lilly Corporate Center</senderstreetaddress>
			<sendercity>Indianapolis</sendercity>
			<senderstate>IN</senderstate>
			<senderpostcode>46285</senderpostcode>
			<sendercountrycode>US</sendercountrycode>
			<sendertel>2770207</sendertel>
			<sendertelcountrycode>317</sendertelcountrycode>
			<senderfax>8666441697</senderfax>
		</sender>
		<receiver>
			<receivertype>2</receivertype>
			<receiverorganization>Food and Drug Administration - CDER</receiverorganization>
			<receiverdepartment>Office of Surveillance and Epidemiology</receiverdepartment>
			<receivertitle>Mr</receivertitle>
			<receivergivename>Roger</receivergivename>
			<receiverfamilyname>Goetsch</receiverfamilyname>
			<receiverstreetaddress>12300 TwinbrookParkway, Suite 240</receiverstreetaddress>
			<receivercity>Rockville</receivercity>
			<receiverstate>MD</receiverstate>
			<receiverpostcode>20851</receiverpostcode>
			<receivercountrycode>US</receivercountrycode>
			<receivertel>3017709299</receivertel>
			<receivertelcountrycode>001</receivertelcountrycode>
			<receiverfax>3017706614</receiverfax>
			<receiverfaxcountrycode>001</receiverfaxcountrycode>
			<receiveremailaddress>roger.goetsch@fda.hhs.gov</receiveremailaddress>
		</receiver>
		<patient>
			<patientinitial>JGL</patientinitial>
			<patientonsetage>72</patientonsetage>
			<patientonsetageunit>801</patientonsetageunit>
			<patientsex>2</patientsex>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Type 2 diabetes mellitus</patientepisodename>
			</medicalhistoryepisode>
			<reaction>
				<primarysourcereaction>Breath shortness</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Breath shortness</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Dyspnoea</reactionmeddrapt>
				<termhighlighted>4</termhighlighted>
				<reactionstartdateformat>610</reactionstartdateformat>
				<reactionstartdate>201212</reactionstartdate>
				<reactionoutcome>1</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Abdominal discomfort</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Abdominal discomfort</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Abdominal discomfort</reactionmeddrapt>
				<termhighlighted>4</termhighlighted>
				<reactionstartdateformat>610</reactionstartdateformat>
				<reactionstartdate>201212</reactionstartdate>
				<reactionoutcome>1</reactionoutcome>
			</reaction>
			<test>
				<testname>X-ray</testname>
				<moreinformation>1</moreinformation>
			</test>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>HUMALOG LISPRO</medicinalproduct>
				<obtaindrugcountry>KR</obtaindrugcountry>
				<drugauthorizationnumb>20-563</drugauthorizationnumb>
				<drugauthorizationcountry>US</drugauthorizationcountry>
				<drugauthorizationholder>Eli Lilly and Company</drugauthorizationholder>
				<drugstructuredosagenumb>6</drugstructuredosagenumb>
				<drugstructuredosageunit>025</drugstructuredosageunit>
				<drugseparatedosagenumb>2</drugseparatedosagenumb>
				<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition>804</drugintervaldosagedefinition>
				<drugdosagetext>6 u, bid</drugdosagetext>
				<drugdosageform>Injection</drugdosageform>
				<drugadministrationroute>058</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Type 2 diabetes mellitus</drugindication>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>20121128</drugstartdate>
				<actiondrug>4</actiondrug>
				<activesubstance>
					<activesubstancename>INSULIN, LISPRO</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Abdominal discomfort</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>NHCP</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Abdominal discomfort</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>NHCP</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Dyspnoea</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>NHCP</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Dyspnoea</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>NHCP</drugresult>
				</drugreactionrelatedness>
			</drug>
			<summary>
				<narrativeincludeclinical>This spontaneous case, reported by a consumer via a patient support program nurse, who contacted the company to report an adverse event, concerns a 72 years old Asian female patient. Additional information received from the consumer via a patient support program nurse.

Medical history: type 2 diabetes mellitus.  Concomitant medications were not provided.

The patient received insulin lispro (Humalog; KwikPen) 6 units/ 10 units bid subcutaneously for treatment of type II diabetes mellitus on 28Nov2012.  Around 12Dec2012 or 13Dec2012, reported as four to five days prior to report of 17Dec2012, the patient experienced breath shortness and abdominal discomfort that were continued.  On 14Dec2012 the patient was hospitalized for the events.  The patient received an x-ray scan in the hospital, results were pending.  No other laboratory results, treatment measures were provided. On an unknown date in late Dec-2012, the patient was transferred to another hospital with an unknown admitting diagnosis because there was no more treatment the hospital doctor could do.  On 08-Jan-2013, the patient was discharged from the second hospitalization. No additional information regarding the hospitalization was provided. At the time of report, blood glucose was well controlled and the outcome of the events was recovered.  Insulin lispro therapy was continued.

Update15-Jan-2013: Additional information was received from the consumer via patient support program on 14-Jan-2013. Updated outcome of events to recovered. Updated narrative. No other changes were made.</narrativeincludeclinical>
			</summary>
		</patient>
	</safetyreport>
</ichicsr>
